Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | ICMT | O60725 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 4/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.35 |
| ▸ | GABRP | O00591 | 1/20 | 0.35 |
| ▸ | GABRD | O14764 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.35 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL782124 | 0.90 | L3MBTL1 (0.41) | TYRCA12CA1CA2CA9 | |
| SCHEMBL780340 | 0.82 | GPR35 (0.38) | CA12CA1CA2CA9KDM4E | |
| SCHEMBL5889466 | 0.79 | HTT (0.39) | KDM4EHSD17B10 | |
| SCHEMBL8657835 | 0.72 | TYR (0.38) | TYRCA12CA1CA2CA9 | |
| SCHEMBL781811 | 0.72 | TDP1 (0.45) | KDM4EALDH1A1HSD17B10MCL1GAA | |
| SCHEMBL8102670 | 0.72 | KDM4E (0.38) | TYRCA12CA1CA2CA9 | |
| SCHEMBL1606352 | 0.71 | CNR2 (0.43) | MCL1CNR2 | |
| SCHEMBL12438310 | 0.71 | LMNA (0.41) | CA12CA1CA2CA9KDM4E | |
| Hydrochloric Acid SCHEMBL7049628 | 0.71 | TDP1 (0.44) | KDM4EALDH1A1HSD17B10MCL1GAA | |
| SCHEMBL22066872 | 0.70 | TYR (0.42) | TYRCA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071628-A1 | TOPICAL THERAPEUTIC AGENT FOR OPHTHALMIC DISEASES COMPRISING COMPOUND CAPABLE OF BINDING SPECIFICALLY TO DNA SEQUENCE | NIHON UNIVERSITY (JP) | 2012-03-22 | — | — | US | disclosed |
| US-20110046070-A1 | GENE EXPRESSION INHIBITOR SELECTIVE FOR MATRIX METALLOPROTEINASE-9 GENE | NIHON UNIVERSITY (JP) | 2011-02-24 | — | — | US | disclosed |
| US-7888516-B2 | transforming growth factor (TGF- beta ) gene expression inhibitors comprising a pyrrole-imidazole polyamides, used as a therapeutic agent for diseases associated with the production of TGF- beta; drugs; side effect reduction | NIHON UNIVERSITY (JP) | 2011-02-15 | — | — | US | disclosed |
| EP-2266583-A1 | GENE EXPRESSION INHIBITOR SELECTIVE FOR MATRIX METALLOPROTEINASE-9 GENE | Nihon University (JP) | 2010-12-29 | — | — | EP | disclosed |
| US-7807844-B2 | TGF-β gene expression inhibitor | NIHON UNIVERSITY (JP) | 2010-10-05 | — | — | US | disclosed |
| US-20080255368-A1 | Tgf-ß Gene Expression Inhibitor | NIHON UNIVERSITY (JP) | 2008-10-16 | — | — | US | disclosed |
| US-20080103187-A1 | Tgf-Beta Gene Expression Inhibitor | GENTIER BIOSYSTEMS, INC. (JP) | 2008-05-01 | — | — | US | disclosed |
| EP-1779850-A1 | TGF- GENE EXPRESSION INHIBITOR | Nihon University (JP) | 2007-05-02 | — | — | EP | disclosed |
| CN-1845733-A | TGF-beta gene expression inhibitors | UNIV NIHON (JP) | 2006-10-11 | — | — | CN | disclosed |
| US-7067622-B2 | Method of the solid phase synthesis of pyrrole-imidazole polyamide | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2006-06-27 | — | — | US | disclosed |
| US-20040171799-A1 | Method of the solid phase synhesis of pyrrole-imidazole polyamide | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2004-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171799-A1 | Method of the solid phase synhesis of pyrrole-imidazole polyamide | PCNA, POLH, PNISR | TYR 2453/4885CA12 854/4885CA1 1474/4885 |
| US-20120071628-A1 | TOPICAL THERAPEUTIC AGENT FOR OPHTHALMIC DISEASES COMPRISING COMPOUND CAPABLE OF BINDING SPECIFICALLY TO DNA SEQUENCE | POLH, POLB, POLK | TYR 1487/4885CA12 2036/4885CA1 3771/4885 |
| US-20080255368-A1 | Tgf-ß Gene Expression Inhibitor | GABRP, GABRB2, GABRB1 | TYR 4399/4885CA12 4475/4885CA1 3863/4885 |
| US-20110046070-A1 | GENE EXPRESSION INHIBITOR SELECTIVE FOR MATRIX METALLOPROTEINASE-9 GENE | GABRP, GABRD, MMP9 | TYR 3009/4885CA12 1051/4885CA1 424/4885 |
| US-20080103187-A1 | Tgf-Beta Gene Expression Inhibitor | TGFBR1, TGFBR2, SMAD2 | TYR 4290/4885CA12 4599/4885CA1 4045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.